CandlesenseCandlesense
LLY•benzinga•

Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial

Summary

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week head-to-head trial.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on May 12, 2025 by benzinga

← Back to LLY News
    Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial | LLY Stock News | Candlesense